Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NE 3107

Drug Profile

NE 3107

Alternative Names: 17α-ethynyl-5-androstene-3β,7β,17β-triol; HE 3286; NE3107; Triolex

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hollis-Eden Pharmaceuticals
  • Developer Harbor Therapeutics; National Institutes of Health (USA); NeurMedix
  • Class Anti-inflammatories; Antiepileptic drugs; Antihyperglycaemics; Antiparkinsonians; Hormones; Obesity therapies; Small molecules
  • Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Phase I Alzheimer's disease; Cognition disorders; Migraine; Myositis; Parkinson's disease
  • Preclinical Amyotrophic lateral sclerosis; Drug-induced dyskinesia; Huntington's disease
  • Discontinued Cystic fibrosis; Epilepsy; Glaucoma; Optic neuritis; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Ulcerative colitis; Uveitis

Most Recent Events

  • 02 Aug 2019 Discontinued - Preclinical for Glaucoma in USA (PO) (NeurMedix pipeline, July 2019)
  • 02 Aug 2019 Discontinued - Preclinical for Optic neuritis in USA (PO) (NeurMedix pipeline, July 2019)
  • 02 Aug 2019 Discontinued - Preclinical for Type 1 diabetes mellitus in USA (PO) (NeurMedix pipeline, July 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top